Who we are
SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research based on the unique contrast theory.
Its unique Diffusion Optics Technology™️ is based on these ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to mimic more natural contrast on the retina — a method intended to reduce myopia progression in children.
The treatment has completed the three years pivotal multisite clinical study.
Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.
